Nifty

:

22402.40

Sensex

:

73852.94

34.40 (0.15%)
114.49 (0.16%)

Login

Nifty
Sensex

:
:

22402.40
73852.94

34.40 (0.15%)
114.49 (0.16%)

Fredun Pharmaceuticals Ltd.

Pharmaceuticals & Drugs

Rating :

53/99

BSE: 539730 | NSE: Not Listed

Watchlist

NSE BSE

827.60

23-Apr-2024

Open
High
Low
Previous Close

770.00
830.00
765.50
765.20

Volume
Traded Value (lacs)
52 Week High
52 Week Low

457
101.80
1249.00
650.00

Stock Summary

Market Cap(Crs)
Stock P:E
Face Value

390.76
27.04
10

Enterprise Value(Crs)
Dividend Yield
Price:Book Value

453.80
0.08%
3.28

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

10 Years
5 Years
3 Years

29.15
23.14
27.07

EBITDA CAGR (%)

10 Years
5 Years
3 Years

35.04
23.51
25.29

PAT CAGR (%)

10 Years
5 Years
3 Years

46.34
19.37
75.20

P:E (Median)

8 Years
5 Years
3 Years

46.69
45.94
58.28

P:BV (Average)

8 Years
5 Years
3 Years

4.27
4.27
4.89

EV:EBITDA (Average)

8 Years
5 Years
3 Years

18.63
18.67
22.57

Quarterly Results

Standalone Figures in Rs. Crores /

Consolidated

Description Dec 23 Dec 22 Var% Sep 23 Sep 22 Var% Jun 23 Jun 22 Var% Mar 23 Mar 22 Var%
Net Sales 87.01 77.96 11.61% 81.98 70.32 16.58% 62.05 48.42 28.15% 79.80 71.84 11.08%
Expenses 76.49 70.65 8.27% 72.38 63.53 13.93% 54.44 44.55 22.20% 67.54 66.45 1.64%
EBITDA 10.52 7.31 43.91% 9.61 6.80 41.32% 7.61 3.87 96.64% 12.26 5.40 127.04%
EBIDTM 12.09% 9.37% 11.72% 9.66% 12.26% 7.99% 15.36% 7.51%
Other Income 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0
Interest 3.77 1.95 93.33% 2.90 1.86 55.91% 2.61 1.91 36.65% 3.55 1.72 106.40%
Depreciation 0.99 0.74 33.78% 0.94 0.72 30.56% 0.92 0.65 41.54% 0.70 0.58 20.69%
PBT 5.76 4.62 24.68% 5.77 4.21 37.05% 4.08 1.31 211.45% 8.01 3.09 159.22%
Tax 1.54 1.16 32.76% 1.83 1.06 72.64% 1.68 0.36 366.67% 4.12 0.79 421.52%
PAT 4.22 3.46 21.97% 3.94 3.15 25.08% 2.40 0.94 155.32% 3.89 2.30 69.13%
PATM 4.85% 4.43% 4.80% 4.48% 3.87% 1.95% 4.88% 3.20%
EPS 8.98 7.36 22.01% 8.38 6.71 24.89% 5.11 2.01 154.23% 8.28 4.89 69.33%

Description Dec 23 Dec 22 Var% Sep 23 Sep 22 Var% Jun 23 Jun 22 Var% Mar 23 Mar 22 Var%
Net Sales 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0
Expenses 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0
EBITDA 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0
EBIDTM 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Other Income 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0
Interest 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0
Depreciation 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0
PBT 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0
Tax 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0
PAT 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0
PATM 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EPS 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0

Annual Results

Standalone Figures in Rs. Crores

Right to Left

Description TTM Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16 Mar 15 Mar 14
Net Sales 310.84 274.68 224.46 133.89 112.77 97.02 59.55 56.70 42.32 25.33 21.28 Net Sales Growth 15.75% 22.37% 67.65% 18.73% 16.23% 62.92% 5.03% 33.98% 67.07% 19.03% Cost Of Goods Sold 226.20 208.68 177.10 102.25 81.75 59.88 39.51 24.57 19.04 15.31 9.73 Gross Profit 84.64 65.99 47.35 31.65 31.02 37.14 20.04 32.12 23.29 10.02 11.56 GP Margin 27.23% 24.02% 21.10% 23.64% 27.51% 38.28% 33.65% 56.65% 55.03% 39.56% 54.32% Total Expenditure 270.85 245.85 210.55 124.55 104.44 86.99 53.84 53.37 38.42 23.67 19.85 Power & Fuel Cost - 3.37 3.49 2.94 3.10 2.75 1.60 1.64 1.17 0.84 0.62 % Of Sales - 1.23% 1.55% 2.20% 2.75% 2.83% 2.69% 2.89% 2.76% 3.32% 2.91% Employee Cost - 11.53 10.66 8.66 8.95 8.04 5.19 4.92 3.83 3.22 2.84 % Of Sales - 4.20% 4.75% 6.47% 7.94% 8.29% 8.72% 8.68% 9.05% 12.71% 13.35% Manufacturing Exp. - 7.29 4.41 3.13 3.58 4.03 1.21 15.32 9.47 0.70 3.37 % Of Sales - 2.65% 1.96% 2.34% 3.17% 4.15% 2.03% 27.02% 22.38% 2.76% 15.84% General & Admin Exp. - 9.66 8.72 5.47 5.19 7.13 3.57 3.34 1.93 1.72 1.51 % Of Sales - 3.52% 3.88% 4.09% 4.60% 7.35% 5.99% 5.89% 4.56% 6.79% 7.10% Selling & Distn. Exp. - 4.95 5.61 1.77 1.76 2.59 2.54 3.46 2.71 1.64 0.47 % Of Sales - 1.80% 2.50% 1.32% 1.56% 2.67% 4.27% 6.10% 6.40% 6.47% 2.21% Miscellaneous Exp. - 0.36 0.56 0.33 0.11 2.57 0.21 0.11 0.27 0.24 0.47 % Of Sales - 0.13% 0.25% 0.25% 0.10% 2.65% 0.35% 0.19% 0.64% 0.95% 6.20% EBITDA 40.00 28.83 13.91 9.34 8.33 10.03 5.71 3.33 3.90 1.66 1.43 EBITDA Margin 12.87% 10.50% 6.20% 6.98% 7.39% 10.34% 9.59% 5.87% 9.22% 6.55% 6.72% Other Income 0.00 1.84 1.63 1.40 0.52 0.58 0.16 1.91 0.86 0.49 0.36 Interest 12.83 10.35 4.78 4.37 4.47 3.12 1.95 1.87 2.06 1.05 0.81 Depreciation 3.55 2.81 2.16 2.00 1.88 1.33 1.29 1.14 0.80 0.55 0.53 PBT 23.62 17.51 8.60 4.37 2.49 6.16 2.64 2.23 1.90 0.55 0.45 Tax 9.17 6.70 2.26 1.19 0.59 1.70 0.89 0.80 0.77 0.26 0.21 Tax Rate 38.82% 38.26% 26.28% 37.07% 23.69% 27.60% 33.71% 35.87% 41.85% 50.00% 46.67% PAT 14.45 10.81 6.34 2.01 1.90 4.46 1.75 1.43 1.07 0.26 0.24 PAT before Minority Interest 14.45 10.81 6.34 2.01 1.90 4.46 1.75 1.43 1.07 0.26 0.24 Minority Interest 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 PAT Margin 4.65% 3.94% 2.82% 1.50% 1.68% 4.60% 2.94% 2.52% 2.53% 1.03% 1.13% PAT Growth 46.70% 70.50% 215.42% 5.79% -57.40% 154.86% 22.38% 33.64% 311.54% 8.33% EPS 30.74 23.00 13.49 4.28 4.04 9.49 3.72 3.04 2.28 0.55 0.51

Results Balance Sheet

Standalone Figures in Rs. Crores

Right to Left

Description Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16 Mar 15 Mar 14
Shareholder's Funds 96.38 68.06 43.07 41.32 38.99 22.16 7.26 3.96 3.08 2.85 Share Capital 4.53 4.43 3.99 3.99 3.99 3.43 4.87 2.62 2.62 2.62 Total Reserves 83.52 63.42 39.08 37.33 35.00 18.74 2.39 1.34 0.46 0.23 Non-Current Liabilities 54.74 45.18 32.09 14.07 12.51 4.06 8.37 7.31 3.69 2.69 Secured Loans 48.93 42.04 29.11 11.50 10.64 0.00 0.00 0.00 0.00 1.97 Unsecured Loans 0.00 0.00 0.00 0.00 0.00 0.00 7.24 6.19 2.94 0.03 Long Term Provisions 1.96 1.71 1.60 1.63 1.08 3.25 0.28 0.43 0.21 0.21 Current Liabilities 106.17 73.75 86.46 85.99 53.41 53.04 40.47 31.93 16.22 12.11 Trade Payables 59.34 48.62 59.96 46.22 33.70 38.92 22.83 16.27 6.99 5.10 Other Current Liabilities 4.94 11.62 14.84 13.79 8.94 1.33 7.75 7.18 2.82 1.91 Short Term Borrowings 37.60 10.72 10.53 23.41 8.63 9.90 7.58 6.85 5.10 4.38 Short Term Provisions 4.29 2.79 1.13 2.57 2.13 2.89 2.31 1.62 1.31 0.72 Total Liabilities 257.29 186.99 161.62 141.38 104.91 79.26 56.10 43.20 22.99 17.65 Net Block 38.93 32.34 30.35 30.97 31.35 16.28 20.50 14.51 7.92 7.02 Gross Block 51.54 42.14 37.99 36.61 35.11 25.00 27.93 20.80 13.40 12.10 Accumulated Depreciation 12.61 9.80 7.64 5.64 3.76 8.71 7.43 6.29 5.49 5.08 Non Current Assets 41.07 34.34 31.54 32.05 32.39 27.78 20.85 14.92 9.81 7.69 Capital Work in Progress 0.00 0.00 0.00 0.00 0.00 11.15 0.00 0.00 1.41 0.00 Non Current Investment 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Long Term Loans & Adv. 2.13 2.00 1.18 1.08 1.03 0.35 0.35 0.31 0.48 0.67 Other Non Current Assets 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.11 0.00 0.00 Current Assets 216.21 152.65 130.08 109.32 72.52 51.48 35.24 28.28 13.08 9.96 Current Investments 0.31 0.06 0.06 0.05 0.00 0.00 0.00 0.00 0.00 0.00 Inventories 150.12 46.46 67.57 50.46 40.78 18.43 6.94 10.27 4.29 3.58 Sundry Debtors 34.56 90.27 41.08 38.97 17.78 15.26 20.38 11.40 5.19 3.43 Cash & Bank 3.44 2.07 1.13 3.06 1.47 1.45 0.75 1.39 0.60 0.42 Other Current Assets 27.78 0.58 0.36 0.29 12.49 16.35 7.18 5.22 3.00 2.54 Short Term Loans & Adv. 27.03 13.20 19.89 16.49 0.75 7.70 6.31 5.01 1.05 0.59 Net Current Assets 110.04 78.90 43.63 23.33 19.11 -1.56 -5.23 -3.65 -3.14 -2.14 Total Assets 257.28 186.99 161.62 141.37 104.91 79.26 56.09 43.20 23.00 17.65

Cash Flow

Standalone Figures in Rs. Crores

Right to Left

Description Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16 Mar 15 Mar 14
Cash From Operating Activity -14.41 -2.38 0.17 -10.64 0.84 17.30 3.97 3.33 1.78 -0.68 PBT 17.46 8.58 2.01 2.35 6.18 1.75 2.23 1.83 0.52 0.45 Adjustment 11.70 7.82 8.65 6.03 2.08 2.67 2.00 1.74 1.15 0.37 Changes in Working Capital -43.57 -18.77 -10.50 -19.02 -7.43 12.88 -0.25 -0.25 0.11 -1.51 Cash after chg. in Working capital -14.41 -2.38 0.17 -10.64 0.84 17.30 3.97 3.33 1.78 -0.68 Interest Paid 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Tax Paid 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Other Direct Exp. Paid 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Extra & Other Items 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Cash From Investing Activity -9.40 -4.14 -1.39 -1.49 -5.25 -8.21 -7.13 -5.99 -3.00 -1.52 Net Fixed Assets -9.40 -4.15 -1.38 -1.50 1.04 -8.22 -7.13 -5.99 -2.71 -1.52 Net Investments -0.25 0.00 -0.01 -0.05 0.00 0.00 0.00 0.00 0.00 0.00 Others 0.25 0.01 0.00 0.06 -6.29 0.01 0.00 0.00 -0.29 0.00 Cash from Financing Activity 25.18 7.47 -0.71 13.73 4.43 -8.38 2.52 3.45 1.40 2.05 Net Cash Inflow / Outflow 1.36 0.94 -1.93 1.59 0.01 0.70 -0.64 0.79 0.18 -0.15 Opening Cash & Equivalents 2.07 1.13 3.06 1.47 1.45 0.75 1.39 0.60 0.42 0.57 Closing Cash & Equivalent 3.44 2.07 1.13 3.06 1.47 1.45 0.75 1.39 0.60 0.42

Financial Ratios

Standalone

Right to Left

Description Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16 Mar 15 Mar 14
Book Value (Rs.) 194.27 153.07 107.96 103.57 97.73 64.71 20.14 15.68 11.50 10.97 ROA 4.86% 3.63% 1.33% 1.54% 4.84% 2.59% 2.88% 3.23% 1.26% 1.50% ROE 13.86% 11.42% 4.77% 4.74% 14.59% 13.02% 33.88% 33.46% 9.68% 9.79% ROCE 18.35% 13.15% 9.53% 10.36% 20.56% 15.90% 18.16% 24.67% 14.23% 14.50% Fixed Asset Turnover 5.86 5.60 3.59 3.14 3.23 2.25 2.33 2.47 1.99 1.91 Receivable days 82.94 106.79 109.11 91.85 62.16 109.23 102.30 71.54 62.01 45.29 Inventory Days 130.61 92.72 160.89 147.66 111.37 77.73 55.39 62.77 56.62 57.45 Payable days 94.41 111.88 189.53 178.44 158.25 217.97 146.17 106.16 100.81 86.92 Cash Conversion Cycle 119.14 87.63 80.47 61.07 15.28 -31.02 11.52 28.15 17.82 15.82 Total Debt/Equity 0.98 0.78 0.92 0.84 0.49 0.45 2.53 3.92 3.06 2.49 Interest Cover 2.69 2.80 1.73 1.56 2.97 2.36 2.19 1.89 1.50 1.56

Top Investors:

nikhil kishorchandra vora

arun kumar mukherjee

Annual Reports:

News Update:

Fredun Pharma - Quarterly Results
14th Feb 2024, 19:24 PM

Read More
Fredun Pharmaceuticals gets orders worth Rs 28 crore from SEA countries
12th Feb 2024, 12:41 PM

The company has also initiated the development of three new molecules
Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.

Feedback